Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called plasma cells, which are types of white blood ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

Last month however saw the approval of its first direct competitor – Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) – which was given the nod by the FDA as a third-line therapy for myeloma.

GSK continues to build the case for its multiple myeloma therapy Blenrep ... Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM ...

French pharma giant Sanofi (Euronext: SAN) has secured European Union approval for Sarclisa (isatuximab) for certain people ...

human monoclonal antibody against CD38 antigen, produced in a mammalian cell line. It is formulated as solution and concentrate solution for intravenous route of administration. Daratumumab is ...

The new approvals are a continuation of researchers’ efforts to find combinations of different therapies that can lead to ...